Study S003339

A Phase IIb Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD5004 in Participants Living With Obesity or Overweight With Comorbidity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06579092
Acronym: VISTA
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: COMPLETED
Enrollment: 310
Start: 2024-10-08
Primary completion: 2025-11-21
Lead sponsor: AstraZeneca
Conditions: Obesity or Overweight
Interventions: DRUG:AZD5004; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: REGISTRY:2024-513691-18-00

Registered primary outcomes

Percent change in body weight from baseline [26 weeks]
Achieved Weight Loss ≥ 5% From Baseline [26 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0012620	Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial. Davies MJ, Lancet (London, England)	2026	Randomized trial	PMID 42259337 DOI	cites ClinicalTrials.gov:NCT06579092; registry reference DERIVED:42259337